vs
Side-by-side financial comparison of Arcellx, Inc. (ACLX) and NextPlat Corp (NXPL). Click either name above to swap in a different company.
NextPlat Corp is the larger business by last-quarter revenue ($12.8M vs $8.1M, roughly 1.6× Arcellx, Inc.). NextPlat Corp runs the higher net margin — -40.2% vs -766.0%, a 725.8% gap on every dollar of revenue. On growth, NextPlat Corp posted the faster year-over-year revenue change (-21.1% vs -79.3%). NextPlat Corp produced more free cash flow last quarter ($-339.0K vs $-63.9M). Over the past eight quarters, NextPlat Corp's revenue compounded faster (-14.4% CAGR vs -24.6%).
Arcellx, Inc. is a clinical-stage biotechnology company that develops innovative chimeric antigen receptor T (CAR-T) cell therapies for treating hard-to-treat cancers including hematologic malignancies and solid tumors. Its core pipeline targets unmet oncology medical needs, serving global patient populations and partnering with life sciences stakeholders.
ACLX vs NXPL — Head-to-Head
Income Statement — Q1 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $8.1M | $12.8M |
| Net Profit | $-62.3M | $-5.1M |
| Gross Margin | — | 14.3% |
| Operating Margin | -847.6% | -28.9% |
| Net Margin | -766.0% | -40.2% |
| Revenue YoY | -79.3% | -21.1% |
| Net Profit YoY | -765.1% | -70.6% |
| EPS (diluted) | $-1.13 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $12.8M | ||
| Q3 25 | — | $13.8M | ||
| Q2 25 | — | $13.2M | ||
| Q1 25 | $8.1M | $14.5M | ||
| Q4 24 | $15.3M | $16.2M | ||
| Q3 24 | $26.0M | $15.4M | ||
| Q2 24 | $27.4M | $17.0M | ||
| Q1 24 | $39.3M | $17.5M |
| Q4 25 | — | $-5.1M | ||
| Q3 25 | — | $-2.2M | ||
| Q2 25 | — | $-1.8M | ||
| Q1 25 | $-62.3M | $-1.3M | ||
| Q4 24 | $-47.1M | $-3.0M | ||
| Q3 24 | $-25.9M | $-4.2M | ||
| Q2 24 | $-27.2M | $-5.3M | ||
| Q1 24 | $-7.2M | $-1.5M |
| Q4 25 | — | 14.3% | ||
| Q3 25 | — | 19.9% | ||
| Q2 25 | — | 21.8% | ||
| Q1 25 | — | 23.8% | ||
| Q4 24 | — | 16.8% | ||
| Q3 24 | — | 23.2% | ||
| Q2 24 | — | 34.5% | ||
| Q1 24 | — | 27.8% |
| Q4 25 | — | -28.9% | ||
| Q3 25 | — | -14.5% | ||
| Q2 25 | — | -13.8% | ||
| Q1 25 | -847.6% | -10.2% | ||
| Q4 24 | -348.2% | -14.1% | ||
| Q3 24 | -129.1% | -52.1% | ||
| Q2 24 | -127.8% | -64.1% | ||
| Q1 24 | -40.3% | -10.5% |
| Q4 25 | — | -40.2% | ||
| Q3 25 | — | -15.9% | ||
| Q2 25 | — | -13.5% | ||
| Q1 25 | -766.0% | -9.2% | ||
| Q4 24 | -308.4% | -18.6% | ||
| Q3 24 | -99.4% | -27.4% | ||
| Q2 24 | -99.3% | -31.3% | ||
| Q1 24 | -18.3% | -8.5% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | $-1.13 | $-0.05 | ||
| Q4 24 | $-0.87 | — | ||
| Q3 24 | $-0.48 | $-0.22 | ||
| Q2 24 | $-0.51 | — | ||
| Q1 24 | $-0.14 | $-0.08 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $543.3M | $13.7M |
| Total DebtLower is stronger | — | $1.3M |
| Stockholders' EquityBook value | $416.9M | $17.3M |
| Total Assets | $648.1M | $27.5M |
| Debt / EquityLower = less leverage | — | 0.07× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $13.7M | ||
| Q3 25 | — | $13.9M | ||
| Q2 25 | — | $16.6M | ||
| Q1 25 | $543.3M | $17.7M | ||
| Q4 24 | $587.4M | $20.0M | ||
| Q3 24 | $574.3M | $20.4M | ||
| Q2 24 | $516.7M | $24.9M | ||
| Q1 24 | $573.9M | $23.5M |
| Q4 25 | — | $1.3M | ||
| Q3 25 | — | $1.2M | ||
| Q2 25 | — | $1.2M | ||
| Q1 25 | — | $1.3M | ||
| Q4 24 | — | $1.4M | ||
| Q3 24 | — | $1.5M | ||
| Q2 24 | — | $1.3M | ||
| Q1 24 | — | $1.4M |
| Q4 25 | — | $17.3M | ||
| Q3 25 | — | $21.4M | ||
| Q2 25 | — | $23.5M | ||
| Q1 25 | $416.9M | $25.3M | ||
| Q4 24 | $454.8M | $27.3M | ||
| Q3 24 | $483.0M | $22.5M | ||
| Q2 24 | $487.2M | $26.5M | ||
| Q1 24 | $496.6M | $31.2M |
| Q4 25 | — | $27.5M | ||
| Q3 25 | — | $30.0M | ||
| Q2 25 | — | $31.0M | ||
| Q1 25 | $648.1M | $35.2M | ||
| Q4 24 | $711.3M | $37.1M | ||
| Q3 24 | $764.9M | $41.1M | ||
| Q2 24 | $734.3M | $51.5M | ||
| Q1 24 | $779.7M | $65.1M |
| Q4 25 | — | 0.07× | ||
| Q3 25 | — | 0.05× | ||
| Q2 25 | — | 0.05× | ||
| Q1 25 | — | 0.05× | ||
| Q4 24 | — | 0.05× | ||
| Q3 24 | — | 0.07× | ||
| Q2 24 | — | 0.05× | ||
| Q1 24 | — | 0.04× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-63.1M | $-302.0K |
| Free Cash FlowOCF − Capex | $-63.9M | $-339.0K |
| FCF MarginFCF / Revenue | -786.4% | -2.6% |
| Capex IntensityCapex / Revenue | 9.6% | 0.3% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-122.5M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $-302.0K | ||
| Q3 25 | — | $-2.7M | ||
| Q2 25 | — | $-1.0M | ||
| Q1 25 | $-63.1M | $-2.1M | ||
| Q4 24 | $-46.0M | $-476.0K | ||
| Q3 24 | $30.7M | $-4.6M | ||
| Q2 24 | $-36.2M | $2.3M | ||
| Q1 24 | $-31.9M | $-2.7M |
| Q4 25 | — | $-339.0K | ||
| Q3 25 | — | — | ||
| Q2 25 | — | $-1.1M | ||
| Q1 25 | $-63.9M | $-2.1M | ||
| Q4 24 | $-47.5M | $-508.0K | ||
| Q3 24 | $28.4M | $-4.7M | ||
| Q2 24 | $-39.5M | $2.2M | ||
| Q1 24 | $-38.3M | $-2.7M |
| Q4 25 | — | -2.6% | ||
| Q3 25 | — | — | ||
| Q2 25 | — | -8.0% | ||
| Q1 25 | -786.4% | -14.3% | ||
| Q4 24 | -311.3% | -3.1% | ||
| Q3 24 | 109.2% | -30.6% | ||
| Q2 24 | -144.1% | 13.2% | ||
| Q1 24 | -97.7% | -15.7% |
| Q4 25 | — | 0.3% | ||
| Q3 25 | — | 0.0% | ||
| Q2 25 | — | 0.1% | ||
| Q1 25 | 9.6% | 0.2% | ||
| Q4 24 | 9.8% | 0.2% | ||
| Q3 24 | 8.8% | 0.6% | ||
| Q2 24 | 11.7% | 0.4% | ||
| Q1 24 | 16.4% | 0.4% |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ACLX
Segment breakdown not available.
NXPL
| Healthcare Operations | $9.0M | 70% |
| Ecommerce Revenue | $3.8M | 30% |
